# China NMPA Drug Inspection - Tianma (Anhui) Traditional Chinese Medicine Pieces Technology Co., Ltd. - triangular

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/tianma-anhui-traditional-chinese-medicine-pieces-technology-co-ltd/ea3ad5fd-3c13-4faf-b4fb-8bc41530d8e3/
Source feed: China

> China NMPA drug inspection for Tianma (Anhui) Traditional Chinese Medicine Pieces Technology Co., Ltd. published July 13, 2018. Drug: triangular. The Henan Provincial Food and Drug Administration announced on July 13, 2018, findings from drug inspections revealing f

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from the Henan Provincial Food and Drug Administration regarding four batches of substandard drugs (Issue No. 8, 2018)
- Company Name: Tianma (Anhui) Traditional Chinese Medicine Pieces Technology Co., Ltd.
- Publication Date: 2018-07-13
- Drug Name: triangular
- Inspection Finding: Properties do not meet regulations
- Action Taken: Necessary risk control measures such as sealing up, seizing, and suspending sales will be taken, and the units that source the inspected goods will be investigated and dealt with in accordance with the law.
- Summary: The Henan Provincial Food and Drug Administration announced on July 13, 2018, findings from drug inspections revealing four batches of substandard drugs from three manufacturers. Enshi Hongxiang Pharmaceutical Co., Ltd. produced turmeric (batch 20130108) found to contain undeclared substances, auramine O and golden orange II. Tianma (Anhui) Traditional Chinese Medicine Pieces Technology Co., Ltd. was cited for *Atractylodes lancea* (batch 160602) with non-compliant content and *Sparganium stoloniferum* (batch 20160801) with appearance issues. Anhui Yiyuantang Traditional Chinese Medicine Pieces Technology Co., Ltd.'s *Atractylodes lancea* stir-fried with wheat bran (batch 140306) also failed content specifications. These violations were identified against regulatory standards, including the Chinese Pharmacopoeia (2015 and 2010 editions) and specific State Food and Drug Administration testing method approvals. As a result, the provincial administration mandated immediate risk control measures. These actions included the sealing, seizing, and suspension of sales for the identified substandard drugs. Furthermore, investigations and legal enforcement actions were required against the entities responsible for both production and distribution of these non-compliant products. This announcement underscores the NMPA's commitment to ensuring drug quality and safety within its jurisdiction.

Company: https://www.globalkeysolutions.net/companies/tianma-anhui-traditional-chinese-medicine-pieces-technology-co-ltd/20444e35-fe0d-4727-8e2f-c3504efee4ee/